What if you could just test your blood and determine whether you have or may have dementia? Or Parkinson? Or Down syndrome? Researchers in a new study recently published nature communication, say it is possible. They studied the levels of a protein called neurofilament light chain (NFL) in the blood, and found that they could predict disease—even when the patient was not showing any symptoms. The study’s promise could have wide-ranging implications. Read on to find out if this test might be for you—and to ensure your health and the health of others, don’t miss them. Sure Signs You Have “Long” COVID and Might Not Even Know It.
Simple blood test may be “clinically useful” in identifying diseases including dementia
“We demonstrate that plasma NFL is useful in identifying atypical Parkinsonian disorders in patients with Parkinsonism, dementia in individuals with Down syndrome, dementia among psychiatric disorders, and frontotemporal dementia in patients with cognitive impairment,” say the authors, who were partially funded. by NIHR Maudsley Biomedical Research Center.
“For the first time we have shown in multiple disorders that a biomarker can indicate the presence of underlying neurodegeneration with excellent accuracy,” said study author Dr Abdul Hay. “While it is not specific to any one disorder, it may help in services such as memory clinics as a rapid screening tool to identify whether memory, thinking or psychological problems are the result of neurodegeneration.”
Co-author Professor Ammar Al-Chalabi, from King’s College London, said: “For neurodegenerative diseases such as Alzheimer’s, Parkinson’s or motor neuron disease, a blood test to allow early diagnosis and monitoring of disease progression and response to treatment. Would be very helpful.” and co-lead of the Psychosis and Neuropsychiatry Research Topic at NIHR Maudsley BRC. “Neurofilament light chain is a promising biomarker that may speed the diagnosis of neurodegenerative diseases and shorten clinical trials.”
People with dementia had higher levels than those who did not.
For their research, the authors studied subjects from King’s College London, Lund University and the Alzheimer’s Disease Neuroimaging Initiative who had no symptoms. “This study shows that levels of the neurofilament light chain were specifically increased in adults with Down syndrome who have a genetic predisposition to Alzheimer’s disease,” said co-author Andre Strydem, Professor of Intellectual Disabilities at King’s College London. . “Furthermore, we showed that individuals with a dementia diagnosis had higher levels after the onset of Alzheimer’s disease than those without. This suggests that the new marker could potentially be used to improve the diagnosis of Alzheimer’s in people with Down syndrome. Can be used as a biomarker to show whether treatments are effective Better tolerated in individuals.”
“In conclusion, in two large independent datasets, we have detailed the meaningful strengths and weaknesses of using plasma NFL as a biomarker for neurodegeneration that may be useful in the primary care setting,” they wrote. “Plasma NFL concentrations are increased in several neurodegenerative disorders, but are highest in samples from individuals with ALS, FTD, and DSD. Furthermore, plasma NFL can differentiate between moderate/severe depression from neurogenerative disorders, which is characterized by multiple disorders.” to have a direct effect.” So cross your fingers so that this test becomes widely available, and don’t forget to check out these 7 Ways You’re Ruining Your Body After 60, Experts Say.